Jade Biosciences (Nasdaq:
JBIO), a clinical-stage biotech focused on autoimmune therapies, appointed Edward R. Conner, M.D., as Chief Medical Officer effective April 22, 2026.
Dr. Conner joins from Ardelyx, Inc. where he was CMO; prior roles include CMO at Third Harmonic Bio, Locanabio, Audentes Therapeutics, and Sangamo Therapeutics, plus Medical Director at Genentech.
He will lead clinical and medical strategy, overseeing upcoming milestones:
Phase 1 data for JADE101, Phase 2 trial in IgA nephropathy, and advancement of JADE201 and JADE301.
Dr. Conner holds an M.D. from UC San Francisco, residency at University of Michigan, fellowship at Johns Hopkins, and B.S. from Duke University.
CEO Tom Frohlich highlighted Conner's immunology and translational medicine expertise for pipeline execution.